Nilogen Oncosystems is led by a team of experienced and passionate individuals. Our commitment to testing and customizing immuno-oncology drug development is proven and yields unparalleled results for our clients.
Sigrid M. Volko, Ph.D., CLP | President & CEO
Dr. Volko holds a Ph.D. in Biology from the University of Basel in Switzerland, and worked as a Research Fellow at the Harvard Medical School in Boston. She is an experienced business development professional and a Certified Licensing Professional with more than 14 years of experience in technology transfer at Massachusetts General Hospital in Boston and the Johns Hopkins University in Baltimore.
Soner Altiok, M.D., Ph.D. | Chief Scientific Officer
Dr. Altiok is a Professor of Pathology and Oncological Sciences at the Moffitt Cancer Center and the University of South Florida in Tampa. He holds an M.D. degree from the Medical School of Istanbul in Turkey and a Ph.D. degree in Molecular Cell Biology from the University of Basel in Switzerland. Dr. Altiok completed his postdoctoral training in Boston at the Dana Farber Cancer Institute and the Beth Israel Deaconess Medical Center, and pursued his clinical training in Pathology and Cytopathology at Massachusetts General Hospital, Harvard Medical School. Following his training, he became an Assistant Professor at the Johns Hopkins School of Medicine to continue his clinical and translational research efforts and joined the Moffitt Cancer Center in 2007. As a physician scientist, he has broad expertise in diagnostic pathology, tissue procurement and processing, preclinical cancer models, such as patient-derived ex vivo platforms and mouse xenograft models, as well as designing biomarker-driven clinical trials.
Jenny Kreahling, Ph.D. | Director of Operations
With more than 15 years of experience in research and management, Dr. Kreahling serves as the Director of Operations for Nilogen. Prior to her work with Nilogen, Dr. Kreahling worked as a Research Scientist at the H. Lee Moffitt Cancer Center in Tampa, focusing on the study of pharmacodynamic profiles of tumors to predict and assess response to therapy. Dr. Kreahling has broad experience in Molecular Oncology and patient-derived preclinical models of drug testing. She holds a Ph.D. in Biomedical Sciences from the University of Connecticut and worked as a Postdoctoral Research Fellow at the University of California, Berkeley and completed her postdoctoral training at the H. Lee Moffitt Cancer Center.
Melanie Mediavilla-Varela, Ph.D. | Director of Research
Dr. Mediavilla-Varela holds a Ph.D. in Microbiology and Molecular Genetics from Loma Linda University in California. She pursued her post-doctoral fellowship in Immuno-oncology at the Moffitt Cancer Center in Florida. She has broad expertise in designing and managing translational studies in the oncology and immunology space. She also has a Business Certificate from the University of South Florida in Tampa.